Sarepta Therapeutics, Inc. $SRPT Holdings Increased by EcoR1 Capital LLC

Key Points

• EcoR1 Capital LLC increased its holdings in Sarepta Therapeutics by 67.8%, now owning approximately 1.32% of the company valued at $82,480,000, making it the 7th largest holding in EcoR1's portfolio.
• Sarepta Therapeutics reported earnings of $2.02 per share and revenue of $611.09 million for the quarter, significantly surpassing consensus estimates.
• A number of brokerages have adjusted their ratings on Sarepta, with Scotiabank upgrading it to "sector outperform" and targeting a price of $80.00.

EcoR1 Capital LLC lifted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 67.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,292,386 shares of the biotechnology company's stock after acquiring an additional 522,386 shares during the period. Sarepta Therapeutics makes up approximately 4.9% of EcoR1 Capital LLC's portfolio, making the stock its 7th largest position. EcoR1 Capital LLC owned approximately 1.32% of Sarepta Therapeutics worth $82,480,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Byrne Asset Management LLC bought a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $30,000. Center for Financial Planning Inc. bought a new stake in Sarepta Therapeutics in the 1st quarter worth approximately $31,000. Logan Capital Management Inc. bought a new stake in Sarepta Therapeutics in the 4th quarter worth approximately $61,000. Ancora Advisors LLC grew its position in Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 300 shares during the period. Finally, Pandora Wealth Inc. bought a new stake in Sarepta Therapeutics in the 1st quarter worth approximately $45,000. Institutional investors own 86.68% of the company's stock.

Wall Street Analyst Weigh In

SRPT has been the subject of a number of research analyst reports. Mizuho reaffirmed a "neutral" rating and issued a $14.00 target price (down previously from $40.00) on shares of Sarepta Therapeutics in a research report on Monday, July 21st. Sanford C. Bernstein assumed coverage on shares of Sarepta Therapeutics in a research report on Tuesday, July 29th. They issued a "market perform" rating and a $13.00 target price for the company. JPMorgan Chase & Co. raised shares of Sarepta Therapeutics from an "underweight" rating to a "neutral" rating and set a $24.00 price objective for the company in a research report on Tuesday, July 29th. Needham & Company LLC restated an "underperform" rating on shares of Sarepta Therapeutics in a research note on Monday, July 28th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on shares of Sarepta Therapeutics to $12.00 and gave the company a "sell" rating in a research note on Friday, August 15th. Eight research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have issued a Sell rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics has an average rating of "Hold" and a consensus target price of $43.50.

Sarepta Therapeutics Price Performance

SRPT stock traded up $0.25 during mid-day trading on Friday, hitting $18.71. The company had a trading volume of 5,173,257 shares, compared to its average volume of 8,848,577. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -21.51 and a beta of 0.49. Sarepta Therapeutics, Inc. has a 12-month low of $10.41 and a 12-month high of $138.81. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. The company has a 50-day moving average price of $17.78 and a 200 day moving average price of $43.93.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, topping the consensus estimate of $0.89 by $1.13. The business had revenue of $611.09 million for the quarter, compared to analysts' expectations of $530.66 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business's quarterly revenue was up 68.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.07 EPS. On average, research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.